NYSE:MED Medifast (MED) Stock Forecast, Price & News $82.10 -0.64 (-0.77%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$81.93▼$83.7950-Day Range$82.10▼$103.6752-Week Range$80.52▼$192.44Volume161,492 shsAverage Volume268,481 shsMarket Capitalization$894.07 millionP/E Ratio6.43Dividend Yield8.04%Price Target$110.50 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Medifast MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside34.6% Upside$110.50 Price TargetShort InterestHealthy15.33% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainability-4.12Upright™ Environmental ScoreNews Sentiment0.96Based on 3 Articles This WeekInsider TradingSelling Shares$239,096 Sold Last QuarterProj. Earnings Growth10.16%From $8.86 to $9.76 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.81 out of 5 starsConsumer Staples Sector17th out of 141 stocksMiscellaneous Food Preparations & Kindred Products Industry1st out of 5 stocks 3.0 Analyst's Opinion Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $110.50, Medifast has a forecasted upside of 34.6% from its current price of $82.10.Amount of Analyst CoverageMedifast has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted15.33% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Medifast has recently decreased by 5.78%, indicating that investor sentiment is improving significantly. Previous Next 3.3 Dividend Strength Dividend LeadershipMedifast is a leading dividend payer. It pays a dividend yield of 8.04%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthMedifast has only been increasing its dividend for 3 years.Dividend CoverageThe dividend payout ratio of Medifast is 51.68%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Medifast will have a dividend payout ratio of 67.62% next year. This indicates that Medifast will be able to sustain or increase its dividend. Previous Next 2.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedifast has received a 6.42% net impact score from Upright. The largest positive contribution comes from its "Nutrition" impact, which is mostly driven by its "Meal replacement drinks", "Granola without added sugar", and "Protein shakes" products. See details.Environmental SustainabilityThe Environmental Impact score for Medifast is -4.12. Previous Next 2.2 News and Social Media Coverage News SentimentMedifast has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Medifast this week, compared to 5 articles on an average week.Search InterestOnly 30 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have sold 246.64% more of their company's stock than they have bought. Specifically, they have bought $68,976.00 in company stock and sold $239,096.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of Medifast is held by insiders.Percentage Held by Institutions86.03% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Medifast are expected to grow by 10.16% in the coming year, from $8.86 to $9.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 6.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.34.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 6.43, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 14.97.Price to Book Value per Share RatioMedifast has a P/B Ratio of 5.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Medifast (NYSE:MED) StockMedifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.Read More Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address MED Stock News HeadlinesMay 28, 2023 | msn.comMedifast Holds Value During HeadwindsMay 20, 2023 | americanbankingnews.comMedifast, Inc. (NYSE:MED) to Post Q2 2023 Earnings of $1.44 Per Share, Zacks Research ForecastsMay 28, 2023 | Behind the Markets (Ad)Avoid the upcoming bloodbathBy this time next year, millions of retirees are going to be so broke they'll struggle to keep the heat running, and may have to make hard decisions about which medications they can afford. It's all because of an upcoming government announcement that could make last year's record breaking 7% inflation look like nothing. Get the details that could keep your money safe here >>>May 18, 2023 | americanbankingnews.comMedifast (NYSE:MED) Now Covered by StockNews.comMay 17, 2023 | americanbankingnews.comFY2025 Earnings Forecast for Medifast, Inc. Issued By Zacks Research (NYSE:MED)May 14, 2023 | americanbankingnews.comInsider Buying: Medifast, Inc. (NYSE:MED) Director Buys $67,663.96 in StockMay 12, 2023 | msn.comMedifast: Strong Earnings But Guidance DisappointsMay 6, 2023 | americanbankingnews.comMedifast (NYSE:MED) Downgraded by StockNews.com to "Hold"May 28, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 5, 2023 | americanbankingnews.comDA Davidson Comments on Medifast, Inc.'s Q2 2023 Earnings (NYSE:MED)May 4, 2023 | finance.yahoo.comMedifast, Inc. (NYSE:MED) Q1 2023 Earnings Call TranscriptMay 4, 2023 | americanbankingnews.comMedifast (NYSE:MED) Sets New 12-Month Low Following Analyst DowngradeMay 3, 2023 | americanbankingnews.comMedifast (NYSE:MED) Price Target Cut to $71.00 by Analysts at DA DavidsonMay 2, 2023 | finance.yahoo.comMedifast's (MED) Q1 Earnings Top Estimates, Sales Decline Y/YMay 2, 2023 | finance.yahoo.comQ1 2023 Medifast Inc Earnings CallMay 1, 2023 | finance.yahoo.comMedifast Announces First Quarter 2023 Financial ResultsApril 30, 2023 | americanbankingnews.comMedifast (NYSE:MED) Raised to "Buy" at StockNews.comApril 30, 2023 | americanbankingnews.comMedifast (MED) to Release Quarterly Earnings on MondayApril 17, 2023 | finance.yahoo.comMedifast to Announce Financial Results for the First Quarter Ended March 31, 2023April 12, 2023 | seekingalpha.comMedifast: Looking Attractively Valued Even Amidst Declining FundamentalsApril 10, 2023 | finance.yahoo.comIs Medifast, Inc. (NYSE:MED) Potentially Undervalued?April 8, 2023 | americanbankingnews.comMedifast (NYSE:MED) Sets New 52-Week Low at $95.96April 3, 2023 | finance.yahoo.comMedifast Named to Financial Times' List of The Americas' Fastest Growing CompaniesApril 3, 2023 | seekingalpha.comMedifast: A High Yield But Low Portfolio Size Hold For MeMarch 26, 2023 | americanbankingnews.comMedifast, Inc. (NYSE:MED) to Issue Dividend Increase - $1.65 Per ShareMarch 23, 2023 | finance.yahoo.comMedifast (MED) Down 2.7% Since Last Earnings Report: Can It Rebound?March 22, 2023 | seekingalpha.comMedifast: An Attractive Dividend But Operating Results Need Further ImprovementSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address MED Company Calendar Ex-Dividend for 5/9 Dividend3/27/2023Last Earnings5/01/2023Dividend Payable5/09/2023Today5/28/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products SectorConsumer Staples Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees984Year FoundedN/APrice Target and Rating Average Stock Price Forecast$110.50 High Stock Price Forecast$150.00 Low Stock Price Forecast$71.00 Forecasted Upside/Downside+34.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$12.77 Trailing P/E Ratio6.43 Forward P/E Ratio9.27 P/E GrowthN/ANet Income$143.57 million Net Margins9.27% Pretax Margin11.92% Return on Equity106.70% Return on Assets49.55% Debt Debt-to-Equity RatioN/A Current Ratio1.75 Quick Ratio1.01 Sales & Book Value Annual Sales$1.60 billion Price / Sales0.56 Cash Flow$15.97 per share Price / Cash Flow5.14 Book Value$15.70 per share Price / Book5.23Miscellaneous Outstanding Shares10,890,000Free Float10,637,000Market Cap$894.07 million OptionableOptionable Beta1.24 Key ExecutivesDaniel R. ChardExecutive Chairman & Chief Executive OfficerAnthony TyreeChief Business Operations OfficerJames P. MaloneyChief Financial OfficerNicholas M. JohnsonChief Field Operations OfficerJonathan B. MacKenzieChief Accounting Officer & Vice President-FinanceKey CompetitorsUtz BrandsNYSE:UTZAdecoagroNYSE:AGROB&G FoodsNYSE:BGSArkoNASDAQ:ARKOFranchise GroupNASDAQ:FRGView All CompetitorsInsiders & InstitutionsLegato Capital Management LLCBought 7,924 shares on 5/25/2023Ownership: 0.137%Ameriprise Financial Inc.Bought 388 shares on 5/22/2023Ownership: 0.708%Putnam Investments LLCBought 209 shares on 5/22/2023Ownership: 0.032%JPMorgan Chase & Co.Bought 46,152 shares on 5/18/2023Ownership: 1.531%New York State Common Retirement FundSold 4,189 shares on 5/18/2023Ownership: 0.116%View All Insider TransactionsView All Institutional Transactions MED Stock - Frequently Asked Questions Should I buy or sell Medifast stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares. View MED analyst ratings or view top-rated stocks. What is Medifast's stock price forecast for 2023? 2 equities research analysts have issued 12-month price objectives for Medifast's shares. Their MED share price forecasts range from $71.00 to $150.00. On average, they anticipate the company's stock price to reach $110.50 in the next twelve months. This suggests a possible upside of 34.6% from the stock's current price. View analysts price targets for MED or view top-rated stocks among Wall Street analysts. How have MED shares performed in 2023? Medifast's stock was trading at $115.35 on January 1st, 2023. Since then, MED stock has decreased by 28.8% and is now trading at $82.10. View the best growth stocks for 2023 here. Are investors shorting Medifast? Medifast saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,730,000 shares, an increase of 9.5% from the April 15th total of 1,580,000 shares. Based on an average daily trading volume, of 238,500 shares, the days-to-cover ratio is currently 7.3 days. Currently, 16.3% of the company's shares are sold short. View Medifast's Short Interest. When is Medifast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our MED earnings forecast. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) announced its quarterly earnings data on Monday, May, 1st. The specialty retailer reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.40 by $1.27. The specialty retailer had revenue of $349 million for the quarter, compared to analysts' expectations of $319.50 million. Medifast had a trailing twelve-month return on equity of 106.70% and a net margin of 9.27%. Medifast's revenue for the quarter was down 16.4% on a year-over-year basis. During the same period in the previous year, the company posted $3.59 earnings per share. How often does Medifast pay dividends? What is the dividend yield for Medifast? Medifast announced a quarterly dividend on Thursday, March 16th. Shareholders of record on Tuesday, March 28th will be paid a dividend of $1.65 per share on Tuesday, May 9th. This represents a $6.60 annualized dividend and a dividend yield of 8.04%. The ex-dividend date of this dividend is Monday, March 27th. This is a boost from the stock's previous quarterly dividend of $1.64. Read our dividend analysis for MED. What ETFs hold Medifast's stock? ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC), First Trust SMID Cap Rising Dividend Archievers ETF (SDVY), Roundhill Acquirers Deep Value ETF (DEEP), VictoryShares US Small Cap High Div Volatility Wtd ETF (CSB), WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS), Pacer US Small Cap Cash Cows 100 ETF (CALF), Is Medifast a good dividend stock? Medifast (NYSE:MED) pays an annual dividend of $6.60 per share and currently has a dividend yield of 8.04%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 51.68%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MED will have a dividend payout ratio of 67.62% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for MED. What guidance has Medifast issued on next quarter's earnings? Medifast issued an update on its second quarter earnings guidance on Monday, May, 1st. The company provided EPS guidance of $1.32-$1.44 for the period, compared to the consensus earnings per share estimate of $2.82. The company issued revenue guidance of $250-$270 million, compared to the consensus revenue estimate of $313.20 million. What is Daniel Chard's approval rating as Medifast's CEO? 44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM). What is Medifast's stock symbol? Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED." Who are Medifast's major shareholders? Medifast's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.45%), Renaissance Technologies LLC (5.98%), State Street Corp (3.49%), Dimensional Fund Advisors LP (3.06%), Principal Financial Group Inc. (2.05%) and Geode Capital Management LLC (2.03%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Medifast's stock price today? One share of MED stock can currently be purchased for approximately $82.10. How much money does Medifast make? Medifast (NYSE:MED) has a market capitalization of $894.07 million and generates $1.60 billion in revenue each year. The specialty retailer earns $143.57 million in net income (profit) each year or $12.77 on an earnings per share basis. How many employees does Medifast have? The company employs 984 workers across the globe. How can I contact Medifast? Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The official website for the company is www.medifast1.com. The specialty retailer can be reached via phone at (410) 581-8042, via email at ir@choosemedifast.com, or via fax at 410-581-8070. This page (NYSE:MED) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.